- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 18.03. | Navigating the valley of death: a how-to from an investor's perspective | ||
| 18.03. | R1 Therapeutics raises $77.5m to progress AP306 for hyperphosphatemia | ||
| 18.03. | FDA issues CRL to Aldeyra's reproxalap drug application | ||
| 17.03. | RFK Jr's vaccine overhaul halted by federal judge's ruling | ||
| 17.03. | FDA accepts Sun Pharma's Ilumya sBLA for psoriatic arthritis | ||
| 17.03. | Sentynl and PRG partner for Progerinin licence | ||
| 16.03. | Most London patients go private to access weight loss drugs | ||
| 16.03. | GSK's RSV jab secures FDA label expansion to larger adult population | ||
| 16.03. | Biophytis and LynxKite expand alliance to boost AI-driven drug discovery | ||
| 16.03. | Novartis wins FDA approval for Cosentyx to treat paediatric HS patients | ||
| 13.03. | Parkinson's research reaches "pivotal" stage, but barriers remain | ||
| 13.03. | WHO directs antibiotic development to priority pathogens | ||
| 13.03. | PRISM BioLab partners with Receptor.AI for molecule discovery | ||
| 13.03. | PsiQuantum and National Cancer Center Japan partner on quantum computing | ||
| 12.03. | Vima banks $100m in Series A to progress Parkinson's drug | ||
| 12.03. | Eli Lilly finds impurity in compounded tirzepatide | ||
| 12.03. | Bavarian Nordic and SII sign agreement for chikungunya vaccine production | ||
| 12.03. | Curatis and Neupharma sign development agreement for corticorelin in Japan | ||
| 11.03. | FDA issues warning to Novo Nordisk on unreported semaglutide safety events | ||
| 11.03. | Eli Lilly to invest $3bn in China in anticipation of orforglipron approval | ||
| 11.03. | BioNTech co-founders step down to launch new mRNA venture | ||
| 11.03. | UK health authorities join forces to champion foreign infectious disease trials | ||
| 11.03. | Idorsia and Pharmalink sign agreement to distribute Quviviq | ||
| 11.03. | FDA approves GSK's Wellcovorin for cerebral folate deficiency | ||
| 10.03. | FDA homes in on biosimilar accessibility in new draft guidance |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.